Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients.
Dennis ThomasVanessa M McDonaldSean StevensErin S HarveyMelissa BaraketPhilip BardinJeffrey J BowdenSimon BowlerJimmy ChienLi Ping ChungAndrew GillmanMark HewSandra HodgeAlan JamesChristine JenkinsConstance H KatelarisGregory P KatsoulotosDavid LangtonJoy Wei-Yan LeeGuy MarksMatthew PetersNaghmeh RadhakrishnaPaul N ReynoldsJanet RimmerPathmanathan SivakumaranJohn W UphamPeter WarkIan A YangPeter G GibsonPublished in: Allergy (2023)
Biologic treatment with mepolizumab or omalizumab for severe asthma-induced asthma remission in a subgroup of patients. Remission on treatment may be an achievable treatment target and future studies should consider remission as an outcome measure.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- disease activity
- chronic kidney disease
- peritoneal dialysis
- rheumatoid arthritis
- chronic obstructive pulmonary disease
- randomized controlled trial
- high glucose
- clinical trial
- diabetic rats
- combination therapy
- patient reported outcomes
- systemic lupus erythematosus
- lung function
- cystic fibrosis
- patient reported
- study protocol
- smoking cessation